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Abstract
Background: Individuals affected with DiGeorge and Velocardiofacial syndromes present with both phenotypic diversity and
variable expressivity. The most frequent clinical features include conotruncal congenital heart defects, velopharyngeal
insufficiency, hypocalcemia and a characteristic craniofacial dysmorphism. The etiology in most patients is a 3 Mb recurrent
deletion in region 22q11.2. However, cases of infrequent deletions and duplications with different sizes and locations have also
been reported, generally with a milder, slightly different phenotype for duplications but with no clear genotype-phenotype
correlation to date.
Methods: We present a 7 month-old male patient with surgically corrected ASD and multiple VSDs, and dysmorphic facial
features not clearly suggestive of 22q11.2 deletion syndrome, and a newborn male infant with cleft lip and palate and upslanting
palpebral fissures. Karyotype, FISH, MLPA, microsatellite markers segregation studies and SNP genotyping by array-CGH were
performed in both patients and parents.
Results: Karyotype and FISH with probe N25 were normal for both patients. MLPA analysis detected a partial de novo 1.1 Mb
deletion in one patient and a novel partial familial 0.4 Mb duplication in the other. Both of these alterations were located at a
distal position within the commonly deleted region in 22q11.2. These rearrangements were confirmed and accurately
characterized by microsatellite marker segregation studies and SNP array genotyping.
Conclusion: The phenotypic diversity found for deletions and duplications supports a lack of genotype-phenotype correlation
in the vicinity of the LCRC-LCRD interval of the 22q11.2 chromosomal region, whereas the high presence of duplications in
normal individuals supports their role as polymorphisms. We suggest that any hypothetical correlation between the clinical
phenotype and the size and location of these alterations may be masked by other genetic and/or epigenetic modifying factors.
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Background
DiGeorge syndrome (DGS) and Velocardiofacial syn-
drome (VCFS) are genetic disorders affecting pharyngeal
and neurobehavioural development [1] that result in
conotruncal congenital heart defects (CHD), velopharyn-
geal insufficiency, hypoparathyroidism, thymic aplasia or
hypoplasia, craniofacial dysmorphism, learning difficul-
ties and psychiatric disorders [2,3]. Interstitial microdele-
tions in 22q11.2 have been identified as the underlying
cause in most cases of DGS [4], VCFS [5] and apparently
isolated conotruncal CHD [6].
Deletions in 22q11.2 cluster into a standard 3 Mb dele-
tion in 87% of the cases, a smaller, proximally nested 1.5
Mb deletion in 7% and other atypical deletions, nested,
overlapping or adjacent to the typically deleted region
(TDR) [7,8]. By non-allelic homologous recombination
(NAHR) after asynchronous replication [9], large low-
copy repeats in 22q11.2 (LCR22s A to D) mediate recur-
rent deletions [7], whereas recently described uncommon
deletions are flanked by smaller LCRs (E to H) [10] or
alternative breakpoints [5,11-24].
Different point mutations [25,26], balanced translocation
breakpoints [27-29] and shortest regions of deletion over-
lap (SRO) [11-16,30,31] in 22q11.2 have been compared
in order to identify candidate genes for the 22q11.2 dele-
tion syndrome phenotype. However, no clear genotype-
phenotype correlation has been found [5,32] and identi-
cal alterations, even within members of the same family,
show high phenotypic diversity and variable expressivity
or incomplete penetrance [33-35]. Systematic clinical
sorting of patients with non-overlapping deletions has
recently shown that an ascertainment bias could be eclips-
ing different phenotypes or even what would be different
syndromes [19,23,36].
22q11.2 duplication syndrome has also been recently
characterized as a different clinical entity [37] with fea-
tures overlapping 22q11.2 deletion syndrome [38]. Since
fewer duplications have been reported, it is suspected that
the diagnosis of this condition is also biased [39-43], a
fact supported by its clinical diversity, generally ranging
from a milder, cognitive/behavioral to an apparently nor-
mal phenotype in these patients [41,43-48]. This lower
severity suggests that duplications with sizes that range
from 3 to 6 Mb are less deleterious than deletions [37] and
therefore are more likely to be inherited at reduced pene-
trance [43]. Again, LCRs work as recombination substrates
for these rearrangements [37], and different sizes have
also been described [43,49].
In this paper we present two patients referred to us for
genetic diagnosis of 22q11.2 deletion syndrome. The first
patient was found to harbor an atypical deletion and the
second one an inherited atypical duplication in the distal
segment of the TDR covering LCRs C and D [7]. We dis-
cuss screening diagnostic strategies for patients referred
for 22q11.2 deletion testing as well as the clinical implica-
tions of these findings for a potential genotype-phenotype
correlation.
Methods
Samples and pictures from patients and their families
were obtained after informed consent. Ethical approval
was obtained for this study from the IRB at Hospital Uni-
versitario La Paz in Madrid (HULP-CEIC-PI347). Research
was performed in compliance with the Declaration of
Helsinki.
Patient 1
A male infant was the first child of healthy, non-consan-
guineous parents of age 39 and 36 years. Due to menstrual
dysfunction in the mother, artificial insemination was
performed with an oocyte donation from a woman of
unknown age. The child was born at 37 weeks of gestation
and weighed 2450 g (10th–25th centile). At age 3 months
he was referred to Pediatric Cardiology because of respira-
tory distress and an ASD (ostium secundum type)
together with multiple muscular and perimembranous
VSDs. He was examined by a clinical geneticist and noted
to have some dysmorphic features such as a triangular
facies with a slighty small chin and a broad nose (Figure
1a, b). He had a poor head control which he finally
achieved at the age of 4 months. Cardiovascular surgery
was performed at that time. At age 7 months he was re-
evaluated; his growth parameters were: height 62.5 cm (<
5th centile), weight 5540 g (< 3rd centile) and OFC 41 cm
(5–10th centile). He was not sitting unsupported yet.
Patient 2
A male newborn was born to healthy 37 year-old parents
after Cesarean section due to lack of progress at 33 weeks
of gestation. Birthweight was 2290 g (75th centile). He
was referred to the Neonatology intensive care unit
because of respiratory distress. He was noted to have a
right cleft lip with a complete cleft palate, and upslanting
palpebral fissures with no other significant features on
examination. He made good progress and was finally dis-
charged two weeks later. He was reviewed in clinic at age
five months. His development was within the normal
range. His growth parameters were: height 62 cm, weight
6500 g and OFC 42.5 cm (all measurements between the
10th and 25th centiles) (Figure 1c). His cleft lip had been
repaired and the cleft palate operation was scheduled for
the age of nine months. A later review at age 13 months
and a half showed a good progress and a normal develop-
ment.BMC Medical Genetics 2009, 10:48 http://www.biomedcentral.com/1471-2350/10/48
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Karyotype and FISH
Cytogenetic analysis was performed after standard har-
vesting of peripheral blood lymphocytes. Metaphase
chromosomes were G-banded. Fluorescence in situ
hybridization was performed on peripheral blood lym-
phocytes, with probe N25 (D22S1660–D22S1646)
(Kreatech Diagnostics, Amsterdam, The Netherlands). A
minimum of 15 metaphase cells were assessed under a
fluorescence microscope (Leica Microsystems, Wetzlar,
Germany).
MLPA
Multiplex ligation-dependent probe amplification was
performed on DNA from peripheral blood lymphocytes,
extracted with Puregene DNA Isolation Kit (Gentra Sys-
tems, Minneapolis, MN). Kits P023B, P250 and P324-A1
for DGS/VCFS/CES (MRC-Holland, Amsterdam, The
Netherlands) were used. The three kits test 65 loci on
22q11 (8 on the CES region, 37 within the TDR and 20
adjacent distal to the TDR), 2 on 22q13, 7 on 4q, 1 on 7p,
5 on 8p, 2 on 9q, 9 on 10p, 1 on 10q, 6 on 17p and 2 on
18q, most of them involved in the phenotypes of DGS
and VCFS. Data analysis was made against up to 5 control
samples using the MRC Coffalyser v8 and v9 software [50]
or an in-house Excel spreadsheet.
Microsatellite segregation studies
Eighteen microsatellite markers (CATCH 10, CATCH 20,
CATCH 42, CATCH 41, CATCH 11, D22S311, CATCH 12,
CATCH 13, CATCH 14, CATCH 39, D22S1709, CATCH
38, CATCH 37, CATCH 36, CATCH 35, D22S446bis,
D22S306, D22S303) spanning the region in the vicinity
of LCR22-C and LCR22-D were studied. Markers named
CATCH were designed by Torres-Juan et al [51].
Array Hybridization profiling and Data Analysis
DNAs were quantified using PicoGreen (Invitrogen Cor-
poration, Carlsbad, CA) and a genome-wide scan of
620,901 tag SNPs was conducted on the probands, using
the Illumina Human610-Quad BeadChip according to
the manufacturer's specifications (Illumina, San Diego,
CA). GenCall scores < 0.15 at any locus were considered
"no calls". Image data was analyzed using the Chromo-
some Viewer tool contained in Beadstudio 3.2 (Illumina,
San Diego, CA). The metric used was the log R ratio which
is the log (base 2) ratio of the observed normalized R
value for a SNP divided by the expected normalized R
value [52]. In addition, an allele frequency analysis was
applied for all SNPs. All genomic positions were based
upon NCBI Build 36 (dbSNP version 126).
Results
Karyotype and FISH analysis with probe N25 in both
patients and their parents showed normal results.
However, MLPA testing of both patients and their parents
with kits P023B, P250 and P324-A1 showed a deletion of
5 probes (SNAP29, LZTR1, LCRD probe 06317-L10754,
HIC2 and LCRD probe 06321-L05796) on Patient 1 (Fig-
ure 2a, b), and a duplication of 3 probes (SNAP29, LZTR1
and LCRD probe 06317-L10754) on Patient 2 (Figure 2a,
b) and his mother, uncle, two aunts and maternal grand-
father (not shown). These MLPA loci fall within a shortest
segment of 675.1 kb for the deletion and 207.4 kb for the
duplication, both including the region between LCR22-C
and LCR22-D [7]. On examination, the mother, uncle,
two aunts and maternal grandfather of Patient 2 were all
phenotypically normal.
On the other hand, microsatellite segregation studies were
informative for STRs D22S311, D22S1709 and CATCH 38
in Patient 1, and confirmed a de novo paternal deletion.
STR CATCH 42 showed a triallelic result for both Patient
2 and his mother, whereas CATCH 11 showed such a
result only in the mother. Fluorescence intensity of the
alleles of markers CATCH 41, D22S311 and CATCH 13
suggested a trisomic result (Table 1).
SNP genotyping by array-CGH narrowed down the dele-
tion size to 1092.027 kb (rs165626-rs12170039) in
Patient 1 (Figure 3a) and the duplication size to 377.634
Facial appearance of Patients 1 and 2 Figure 1
Facial appearance of Patients 1 and 2. Patient 1 (a, b); 
Patient 2 (c).BMC Medical Genetics 2009, 10:48 http://www.biomedcentral.com/1471-2350/10/48
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kb (rs17819969-rs11703181) for Patient 2 (Figure 3b).
These results are consistent with MLPA and STRs studies.
Other genomic copy number variations (CNV) observed
in these patients had been previously described in the nor-
mal population [53,54] according to the Database of
Genomic Variants [55] (data not shown). The relative
location of each marker and the deleted and duplicated
segments are shown in Figure 4.
Discussion
The whole phenotypic spectrum of 22q11.2 deletion syn-
drome is contributed by multiple dosage-sensitive genes
across the 22q11.2 region, that are required for normal
development [reviewed in [1]]. Moreover, non-overlap-
ping, atypical deletions do have significantly overlapping
phenotypes, suggesting either, several candidate genes for
the syndrome [13,14,56], a common developmental
pathway [17] or a positional gene effect in 22q11.2
[17,57-59]. On the other hand, phenotypes shown by
identical deletions in 22q11.2 have been suggested to be
modified by parental imprinting [60], unbalanced regula-
tory effects [15,59], recessive mutations or polymor-
phisms unmasked by hemizygosity [59,60],
environmental factors [60] or stochastic events during
morphogenesis [15,61]. Susceptibility to other syndromes
in patients with 22q11.2 deletions has also been pro-
posed [58,62,63]. Phenotypic discordance has been
observed in monozygotic twins with 22q11.2 deletion
syndrome [33,64], a finding that is consistent with both a
genetic and an environmental influence.
In the recent years, several candidate genes reproducing
part of the phenotype in animal models [13,14,26,56,65]
or suspected to change disease predisposition [66-69]
MLPA results of Patients 1 and 2 Figure 2
MLPA results of Patients 1 and 2. Gene dosage of Patient 1 and Patient 2 observed by MLPA. Kit P250 (a) showed deletion 
of probes SNAP29, LZTR1 and HIC2 in Patient 1 and duplication of probes SNAP29 and LZTR1 in Patient 2, whereas kit P324-
A1 (b) showed deletion of both LCRD probes in Patient 1 and duplication of only the proximal one in Patient 2. Data from 
both kits were analysed with Coffalyser v8 and v9, respectively.B
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Table 1: Alleles of STR markers studied in Patient 1 and father and Patient 2 and relatives.
Position Patient 1 Father 1 Patient 2 Mother 2 Father 2 Maternal aunt 2a Maternal aunt 2b Maternal uncle 2 Maternal
grandfather 2
CATCH 10 191,164,96 120 122 NA 120 122 122 120 122 122 122 122 122
CATCH 20 19,245,111 160 160 NA 160 160 162 160 160 160 160
PCQAP* 19,266,745 N N N N N N N N N
LCR-C** 19,354,000–
19,417,000
CATCH 42 19,449,222 99 93 99 93 97 101 93 99 101 97 99 93 99 101 93 99 101 93 99 101 93 101
CATCH 41 19,450,208 NA 169 173 169 173 169 173 173 177 169 173 169 173 169 173 169 173
CATCH 11 19,469,542 197 195 197 195 199 191 195 199 195 199 191 195 199 191 195 199 191 195 199 195 199
D22S311 19,503,575 251 249 255 251 253 249 253 251 249 253 249 253 249 253 249 253
CATCH 12 19,566,292 116 116 116 116 116 116 116 116 116
CATCH 13 19,567,154 143 138 143 138 143 138 143 143 138 143 138 143 138 143 138 143
SNAP29* 19,572,014 del N dup dup N dup dup dup dup
CATCH 14 19,595,454 212 212 215 200 216 227 208 216 227 200 210 208 216 227 208 216 227 208 216 227 216 220 227
CATCH 39 19,640,114 106 106 110 94 102 110 94 102 106 106 110 94 102 106 94 102 106 94 102 106 94 102
LZTR1* 19,679,191 del N dup dup N dup dup dup dup
D22S1709 19,735,440 120 128 126 128 132 126 128 132 128 132 126 128 132 126 128 132 126 128 132 126 132
CATCH 38 19,745,025 157 159 159 159 155 159 159 159 159 159 163
CATCH 37 19,759,833 NA 226 234 230 245 230 245 230 245 230 245 230 245 230 245 230 245
LCR-D** 19,777,000
LCRD 06317-
L10754*
19,779,435 del N dup dup N dup dup dup dupB
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CATCH 36 20,126,412 109 109 109 109 109 109 109 109 109
HIC2* 20,130,631 del NNN N N N N N
LCR-D** 20,242,000
LCRD 06321-
L05796*
20,247,101 del NNN N N N N N
CATCH 35 20,341,833 136 136 150 136 150 136 143 143 150 136 143 136 143 136 143 136 143
D22S446bis 20,343,665 157 157 185 157 180 157 161 165 180 157 161 157 161 157 161 157 161
PPIL2* 20,379,687 N N N N N N N N N
D22S306 20,887,523 106 106 NA NA NA 106 106 106 106
D22S303 21,599,366 212 222 212 222 NA NA NA 212 222 212 222 212 222 212
Alleles are expressed in fragment bp. STR markers are located according to the NCBI Build 36.1, together with the MLPA probes (*) and the LCRs (**). The shortest informative deletion and 
duplication segments by MLPA and STRs are D22S311-LCRD 06321-L05796 and CATCH 42-LCRD 06317-L10754, respectively. Bold text indicates haploinsufficiency or trisomy, two alleles 
listed in bold mean that homozygosity is suspected in one of them, so there are really three alleles. Regular text indicates biallelism. Italic indicates non informative results. del: deletion; dup: 
duplication; N: normal; NA: not available.
Table 1: Alleles of STR markers studied in Patient 1 and father and Patient 2 and relatives. (Continued)BMC Medical Genetics 2009, 10:48 http://www.biomedcentral.com/1471-2350/10/48
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Array-CGH SNP genotyping of Patients 1 and 2 Figure 3
Array-CGH SNP genotyping of Patients 1 and 2. Chromosome 22 plot of Patients 1 (a) and 2 (b). The upper panels 
show the genic dosage (Log R ratio) and the homozygous/heterozygous distribution (B allele frequency) for all the SNPs geno-
typed. Both parameters are used together for interpretation of deletions and duplications. The region showing copy number 
alterations is zoomed in below, indicating the flanking SNPs and the genes in the region. A copy number decrease and loss of 
heterozygosity was found in Patient 1 (pink shading, a), whereas a copy number increase with four different allele populations 
was found in Patient 2 (blue shading, b).BMC Medical Genetics 2009, 10:48 http://www.biomedcentral.com/1471-2350/10/48
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have been identified in 22q11.2. In this context, correla-
tions made within a contiguous gene syndrome will
always be subjected to phenotype exceptions.
Rauch et al [19] described a likely genotype-phenotype
correlation, by comparing the phenotypes of non-over-
lapping deletions in 22q11.2 (Table 2). They concluded
that deletions covering the whole TDR or the proximally
nested 1.5 Mb segment result in a phenotype character-
ized by conotruncal CHDs and typical VCFS, mainly by
effects of haploinsufficiency of TBX1, a gene previously
involved in the expression of these features when mutated
[26], whereas distally nested deletions including CRKL
would present with a milder, atypical phenotype with
uncommon CHDs, developmental delay and mental
impairment. Likewise, distal deletions which are adjacent
to, and do not include the TDR, would generally have
associated non-specific CHDs and very uncommon fea-
tures of 22q11.2 deletion syndrome such as choanal
atresia. Within these deletions, the shortest proximal seg-
ment has been associated with mild learning difficulties
[19]. Recently, additional characteristic features of this
new condition such as prematurity, prenatal and postna-
tal growth retardation, developmental delay, mild skeletal
abnormalities and characteristic facial dysmorphic fea-
tures have been described [23] (Table 2).
The absence of a genotype-phenotype correlation high-
lights the incomplete penetrance associated with altera-
tions in the 22q11.2 region. As an example, an apparently
identical atypical deletion in two reported familial cases
was found to present both inter- and intrafamilial varia-
bility [18,19]. This atypical deletion which spanned the B-
D segment, and which should have been mainly involved
in learning disability and mental retardation, was found
to be associated with a conotruncal CHD in a child of a
deleted father with normal phenotype [18] (Table 2).
Whereas, in the second case, the child developed a more
neurobehavioural phenotype, with an undiagnosed father
Detailed map of the distal TDR in 22q11.2 Figure 4
Detailed map of the distal TDR in 22q11.2. The relative location of the informative MLPA probes (blue font), STRs (black 
font) and SNPs (gray, small-sized font) sizing the shortest deletion and duplication size are shown above the line. Green boxes 
indicate LCRs, purple boxes indicate the discussed genes and the pink bar and the blue bar below the line indicate the deleted 
and the duplicated segment, respectively. Cen: centromere; tel: telomere.BMC Medical Genetics 2009, 10:48 http://www.biomedcentral.com/1471-2350/10/48
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with schizophrenia [19]. Both patients had mild facial
dysmorphism with overlapping features of DGS/VCFS.
In line with this, the only two reported distally nested C-
D deletions similar to that found in Patient 1 are also phe-
notypically discordant [21,70]. Both were located within
this segment that should be associated with the neurobe-
havioural expression. The patient from D'Angelo et al [21]
had mild facial features and a complex neurodevelop-
mental, behavioural and psychiatric spectrum, with a
major depressive disorder in her transmitting mother, but
the patient described by Kurahashi et al [70] had a typical
conotruncal anomaly face syndrome with pulmonary
atresia, tetralogy of Fallot, and facial dysmorphic features.
Our patient had a non-specific CHD and mild facial fea-
tures, barely suggestive of the 22q11.2 deletion syndrome
(Table 2). All these findings, within such a small sample
size, do not reveal strong evidences but suggest that
genetic changes in 22q11.2 are incompletely penetrant
[19] or that maybe genotype-phenotype correlations are
invalid for this specific region [21].
The reason for all these exceptions in the distal TDR might
be the presence of CRKL, a gene that has been involved in
multisystemic affection of cardiac neural crest derivatives
when null-mutated in mice [65]. Otherwise, other genes
in this region seem to be responsible for a more particular
phenotype: certain SNP haplotypes within genes PIK4CA
[66,67] and SNAP29 [68,69] have been recently suggested
to confer a higher risk of developing schizophrenia (Fig-
ure 4).
Recently, high resolution molecular diagnostic techniques
have contributed to map the rearrangements in 22q11.2
Table 2: Observed clinical features in atypical deletions of the LCR intervals in 22q11.2.
LCR interval Rauch 2005 [19] Ben-Shachar 
2008 [23]
García-Miñaur 
2002 [18]
Kurahashi 1996 
[70]
D'Angelo 2007 [21] Patient 1
- ctCHD - ctCHD
A-B - typical VCFS - typical VCFS
- Atypical CHD - ctCHD
B-C - Mild 
dysmorphism
- Mild facial 
dysmorphism
- DD - Father normal
- Learning 
disabilities
- CTAFS: TOF, 
PA
- Mild facial features - Atypical CHD
C-D - Facial 
dysmorphism
- 
Neurodevelopmental, 
behavioural and 
psychiatric spectrum 
disorder
- Atypical facial 
features
- Mother with 
depressive disorder
- Prematurity
- Mild DD - Mild DD
- Prenatal and 
postnatal GR
- Choanal 
atresia
- Learning 
difficulties and/or 
DD
D-E - Atypical 
CHD
- Specific skeletal 
abnormalities
- Characteristic 
facial 
dysmorphism
- Higher risk for 
TA
E-F
CTAFS: conotruncal anomaly face syndrome; ctCHD: conotruncal congenital heart defect; DD: developmental delay; GR: growth retardation; PA: 
pulmonary atresia; TA: truncus arteriosus; TOF: tetralogy of Fallot; VCFS: Velocardiofacial syndrome.BMC Medical Genetics 2009, 10:48 http://www.biomedcentral.com/1471-2350/10/48
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more precisely. In fact, high resolution comparative
genomic hybridization (HR-CGH), real-time quantitative
PCR (qPCR) and high density MLPA (HD-MLPA) have
shown that around 7% of the typical 3 Mb A-D deletions
have atypical distal breakpoints covering HIC2, suggesting
that this gene located within LCR22-D might be involved
in the phenotypic variability among these patients
[20,71,72]. Hic2 may be required for heart development
in mouse [Lammerts van Beuren K and Scambler PJ, per-
sonal communication]. HIC2 might be also involved in
the phenotypic variability of Patient 1 and other patients
reported to carry the C-D deletion [21,70], as well as in
patients with other atypical deletions [15,17,19,20,58].
Screening for duplications at 22q11.2 has no standardized
procedure, as these patients show clinical manifestations,
only some of which are compatible with 22q11.2 deletion
syndrome within a generally milder phenotype
[37,41,43,48]. Different duplication sizes have been
reported [43,48,49], all of them showing a higher ten-
dency to be inherited than deletions [43]. Phenotype cor-
relations to the sizes and locations of these duplications
are even harder to find than in deletions, as the whole
clinical spectrum is still unknown and many of these indi-
viduals overlap normality [41,43].
Patient 2 and his maternal relatives are carriers of an atyp-
ical duplication that maps distal within the TDR. Unlike
common duplications [43,63,73], this novel rearrange-
ment, the smallest one reported to date, has therefore
unknown clinical implications. Polymorphisms and copy
number variants can be defined as alterations of a small
region known to contain no critical genes and that can be
inherited from healthy individuals [41,43]. However, as
proposed for TBX1, other genes in 22q11.2 may have clin-
ical significance when present in a trisomic dosage
[43,74,75]. On the other hand, four other carriers of the
family of Patient 2 show normal phenotype, and the
patient shows cleft palate, a potentially multifactorial
malformation which may be less associated with 22q11.2
duplications than thought [40]. The case that is most sim-
ilar to this duplication was described by Fan et al [76] in a
patient with mental retardation or developmental delay
associated to other malformations, inherited from a phe-
notypically normal father. This 479 kb duplication also
included PCQAP, another gene with a potential involve-
ment in schizophrenia susceptibility [77,78].
Novel and rare rearrangements in such a complex chro-
mosomal region with highly uncertain phenotypic conse-
quences, have uncertain implications for genetic
counseling. High intrafamilial variability and reduced
penetrance are phenotypic effects that hamper the distinc-
tion between pathologic change and polymorphism [79].
In this context, the possibility that the phenotypes of our
patients might not be caused by the observed rearrange-
ments should be reminded. Also, small deletions and
duplications occurring from generation to generation in
this rearranged segment cannot be excluded [80].
Despite having occurred in the same region, our two rear-
rangements, as far as they have been molecularly charac-
terized, are significantly different (Figure 4). The deletion
is more than twice the size of the duplication and includes
HIC2  and the whole LCRs C and D, which are nearly
intact in the duplication. This variation in the breakpoints
location highlights potential differences in the molecular
mechanisms mediating these rearrangements. In fact, the
deletion is too large to be a C-D rearrangement and is pos-
sibly not mediated by non-allelic homologous recombi-
nation between LCRs.
Even for identical rearrangements, genetic counseling and
clinical prognosis is still complex. Genotype-phenotype
correlations made so far in 22q11.2 are compatible with a
clinical outcome modified by environmental/stochastic
events [15,60,61] and eclipsed by regulatory factors
[15,59]. At this moment, the molecular diagnostic tech-
niques we have used are the best screening procedure for
patients with this whole spectrum of overlapping clinical
features, suspected of having any kind of rearrangement in
22q11.2 resulting in a copy number imbalance
[71,81,82].
Conclusion
In summary, we report on the third atypical deletion and
the first atypical duplication in the vicinity of low-copy
repeats C and D in distal 22q11.2 deletion region. The
breakpoints location and sizes make it possible that both
rearrangements may be mediated by different mecha-
nisms or sequences. A complex network of modifying fac-
tors may influence the phenotypic outcome of these
chromosomal aberrations. A systematic literature review
and genotyping of phenotype-associated polymorphisms
can help anticipating the clinical evolution of patients and
understanding the prognosis and predisposition to this
disease.
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